GC Green Cross Participates in the 2025 KASBP Spring Symposium

GC Green Cross announced on the 16th that it participated as the main sponsor of the '2025 Korean American Scientists and Biopharmaceutical Professionals (KASBP) Spring Symposium' held in Maryland, USA, on the 13th and 14th, where it shared its global clinical strategies.

At the '2025 Korean American Scientists and Business Professionals (KASBP) Spring Symposium' held in Maryland, USA, on the 13th and 14th, Euncheol Heo, CEO of GC Green Cross, is giving a presentation. Photo by GC Green Cross

The KASBP Symposium is an event where Korean scientists active in the U.S. pharmaceutical and biotech industries share the latest trends in new drug development. It is held regularly every spring and fall. This year's theme was "Strategies For Success In Clinical Development: Overcoming Regulatory Hurdles And Driving Innovation."

At this event, GC Green Cross presented its U.S. clinical trial and FDA approval experience with 'Aliglo,' as well as clinical strategies for its current rare disease pipeline. The company explained that it focused particularly on development strategies and the current status of clinical research for treatments for Sanfilippo syndrome and Fabry disease.

Sanfilippo syndrome is a rare hereditary disease similar to Hunter syndrome, and is known to occur in approximately one out of every 70,000 children. GC Green Cross stated that it is focusing on developing a treatment for Sanfilippo syndrome based on its successful experience with the Hunter syndrome treatment 'Hunterase,' and aims to launch it in the global market within five years.

In addition, the Fabry disease treatment, which is being co-developed with Hanmi Pharmaceutical, is being developed as a once-monthly subcutaneous injection formulation that improves dosing convenience compared to existing intravenous therapies. Global Phase 1/2 clinical trials are currently underway, and based on strong data from animal models, the company expects to enter the 'Best-In-Class' market.

At the '2025 Korean American Scientists and Biopharmaceutical Professionals (KASBP) Spring Symposium' held in Maryland, USA, on the 13th and 14th, the awardees and officials are taking a group photo. Photo by GC Green Cross

In addition, GC Green Cross annually selects outstanding next-generation Korean American researchers who have demonstrated excellent research achievements to receive the 'KASBP-GC Biopharma Fellowship Award.' This year, the awardees were Jin Young Kang of the Massachusetts Institute of Technology (MIT) and Yoonjae Lee of the Icahn School of Medicine at Mount Sinai (ISMMS), selected based on their potential, accomplishments, and impact in the biopharmaceutical field.

Shin Sugyeong, Head of the Medical Division at GC Green Cross, who gave a presentation at this symposium, said, "I am pleased to have participated in such a meaningful event that can expand the possibilities for cooperation between the Korean and American pharmaceutical and biotech industries," adding, "GC Green Cross will continue to drive innovation in the rare disease field based on our global clinical strategies."